# K092566: Verigene Respiratory Virus Nucleic Acid Test on the Verigene SP System (Rvnatsp)

- Pathway: 510(k) (Traditional)
- Applicant: Nanosphere, Inc.
- Decided: Oct 9, 2009 after 50 days
- Product code: OCC (Respiratory Virus Panel Nucleic Acid Assay System)
- Device class: 2
- Regulation: 21 CFR 866.3980
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 3 generations back to DEN070013 (2008). 4 ancestors in all.
4 later devices descend from it; 2 cite it directly.
0 of 9 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K083088: Verigene Respiratory Virus Nucleic Acid Test, Nanosphere, Inc. (2009) Summary page 1.

## Most influential descendants
- K103209: Verigene Respiratory Virus Nucleic Acid Test +(Rvnat+) (2011), 2 descendants of its own
- K163628: Idylla Respiratory (IFV-RSV) Panel (2017), 0 descendants of its own
- K131584: Imdx Flu a/B and RSV for Abbott M2000 (2013), 0 descendants of its own
- K123197: Verigene C. Difficile Nucleic Acid Test (CDF) (2012), 0 descendants of its own

## Indications for use
The Verigene ® Respiratory Virus Nucleic Acid Test on the Verigene SP System (RVNATsp) is a qualitative multiplex in vitro diagnostic test for the detection and identification of Influenza A Virus, Influenza B Virus, and Respiratory Syncytial Virus (RSV) nucleic acids purified from nasopharyngeal swab specimens obtained from patients symptomatic for viral upper respiratory infection. The test is intended to be used on the Verigene ® SP System as an aid in the differential diagnosis of Influenza A, Influenza B, and RSV infections. The test is not intended to detect Influenza C virus. Negative results do not preclude influenza virus or RSV infection and should not be used as the sole basis for treatment or other management decisions. It is recommended that negative test results be confirmed by culture. Performance characteristics for Influenza A Virus were established when Influenza A/H3 and A/H1 were the predominant Influenza A viruses in circulation. When other Influenza A viruses are emerging, performance characteristics may vary. If infection with a novel Influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

Source page: https://510kreport.com/device/K092566
Methodology: https://510kreport.com/methodology